Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How Should FDA Tell Public About Device Risks? New Advisory Panel Will Help

This article was originally published in The Gray Sheet

Executive Summary

FDA will get advice on how to talk to the public about medical device risks from its new Risk Communication Advisory Committee, announced June 4

You may also be interested in...



FDA Aims To Improve Product Risk Communication Under Strategic Plan

Under a plan unveiled Sept. 30, FDA aims to increase its understanding of appropriate ways to communicate with the public about product risks and to streamline its product risk communication processes

FDA Aims To Improve Product Risk Communication Under Strategic Plan

Under a plan unveiled Sept. 30, FDA aims to increase its understanding of appropriate ways to communicate with the public about product risks and to streamline its product risk communication processes

FDA Hears Experience Of Regional Device Safety Registries

FDA is soliciting ideas from regional programs that gather postmarket data to help design its proposed "Sentinel Network" for medical product safety information

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel